(Q28250892)

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9

7 January 2021

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9

7 January 2021

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9

7 January 2021

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9

7 January 2021

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9

7 January 2021

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9

7 January 2021

Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9

7 January 2021

Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9

7 January 2021

Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9

7 January 2021

Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9

7 January 2021

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9

7 January 2021

A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9

7 January 2021

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9

7 January 2021

A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9

7 January 2021

Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9

7 January 2021

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9

7 January 2021

Fingolimod is a potential novel therapy for multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9

7 January 2021

Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9

7 January 2021

Future clinical challenges in multiple sclerosis: Relevance to sphingosine 1-phosphate receptor modulator therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9

7 January 2021

Emerging oral therapies in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9

7 January 2021

Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9

7 January 2021

T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9

7 January 2021

FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9

7 January 2021

Oral fingolimod (FTY720) for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9

7 January 2021

Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9

7 January 2021

Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9

7 January 2021

Development of oral cladribine for the treatment of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9

7 January 2021

The clinical pharmacokinetics of cladribine

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9

7 January 2021

Cladribine and progressive MS: Clinical and MRI outcomes of a multicenter controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9

7 January 2021

Cladribine in treatment of chronic progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9

7 January 2021

The treatment of chronic progressive multiple sclerosis with cladribine

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9

7 January 2021

A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9

7 January 2021

Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9

7 January 2021

Multiple sclerosis therapies: molecular mechanisms and future

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9

7 January 2021

Linomide in relapsing and secondary progressive MS: part I: trial design and clinical results. North American Linomide Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9

7 January 2021

Linomide in relapsing and secondary progressive MS: part II: MRI results. MRI Analysis Center of the University of Texas-Houston, Health Science Center, and the North American Linomide Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9

7 January 2021

The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9

7 January 2021

Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9

7 January 2021

Insight into the mechanism of laquinimod action

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9

7 January 2021

Treatment with laquinimod reduces development of active MRI lesions in relapsing MS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9

7 January 2021

Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9

7 January 2021

Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9

7 January 2021

Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9

7 January 2021

Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9

7 January 2021

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9

7 January 2021

The changing face of multiple sclerosis clinical trial populations

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9

7 January 2021

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9

7 January 2021

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9

7 January 2021

Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9

7 January 2021

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9

7 January 2021

Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9

7 January 2021

Anti-JC virus antibodies: implications for PML risk stratification

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9

7 January 2021

Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970228-9

7 January 2021